San Diego, United States
Adcentrx Therapeutics, a biotechnology company founded in 2021, is making significant strides in the realm of protein conjugate therapeutic development. With a focus on addressing cancer and other critical illnesses, their unique approach leverages the precision of biologics combined with the potent capabilities of small molecule payloads to create next-generation targeted therapies.
Operating out of the United States, Adcentrx aims to enhance treatment options for patients worldwide. The company successfully secured a $51.00M Series A investment on 24 April 2023, showcasing strong investor confidence. Key players in this funding round included Eight Roads Ventures, F-Prime Capital, Partners Investment, Delta Capital, Quan Capital, Trinity Innovation Fund, Lighthouse Capital 光源资本, and ABio-X.
With cutting-edge research and strategic financial backing, Adcentrx is well-positioned to lead innovations within the sectors of Biotechnology and Pharmaceutical.
